Condition: AML/MDS · Acute Myeloid Leukemia · Myelodysplastic Syndromes · Sponsor: Montefiore Medical Center
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD
This description comes directly from the study's public registry record.
Aditi Shastri, MBBS · 718-920-4826 · ashastri@montefiore.org
Always discuss trial participation with your own doctor first.
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| M.D. Anderson Cancer Center, Department of Leukemia | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05986240